Cabometyx EU

Cabometyx in Europe

This is a promotional website intended for Healthcare Professionals in EU, excluding France

References (CABOMETYX® RCC)

  1. CABOMETYX® Summary of Product Characteristics.
  2. Jubb AM, Pham TQ, Hanby AM, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol. 2004;57(5):504-12.
  3. Nakagawa M, Emoto A, Hanada T, et al.Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma. Br J Urol. 1997;79(5):681-7.
  4. Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24:343–9.
  5. Rankin EB, Fuh KC, Castellini L, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A. 2014;111(37):13373-8.
  6. Zhou L, Liu XD, Sun M, et al.Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687-97.
  7. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591-7.
  8. Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115-25.
  9. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. New Eng J Med. 2015;373(19):1814-23.
  10. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.Lancet Oncol. 2016;17(7):917-27.
  11. Motzer RJ, Escudier B, Powles T, et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer. 2018;118(9):1176-78.
  12. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Feb 21. pii: mdz056. doi: 10.1093/annonc/mdz056. [Epub ahead of print]
  13. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma:N The 2019 update. Eur Urol. 2019;75(5):799–810.
  14. European Association of Urology guidelines on renal cell carcinoma. Available at https://uroweb.org/guideline/renal-cell-carcinoma. [Accessed July 16, 2019].
  15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Kidney Cancer. Version 4.2019 – April 2019.
© Ipsen Group 2019 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU – excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Welcome to Cabometyx.eu website. This website is intended for EU Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.

 

I AM A EU HEALTHCARE PROFESSIONAL

I AM A FRENCH HEALTHCARE PROFESSIONAL

I AM NOT A EU HEALTHCARE PROFESSIONAL